Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Regardless of the newly diagnostic and therapeutic advances, coronary artery disease (CAD) and more explicitly, ST-elevation myocardial infarction (STEMI), remains one of the leading causes of morbidity and mortality worldwide. Thus, early and prompt diagnosis of cardiac dysfunction is pivotal in STEMI patients for a better prognosis and outcome. In recent years, microRNAs (miRNAs) gained attention as potential biomarkers in myocardial infarction (MI) and acute coronary syndromes (ACS), as they have key roles in heart development, various cardiac processes, and act as indicators of cardiac damage. In this review, we describe the current available knowledge about cardiac miRNAs and their functions, and focus mainly on their potential use as novel circulating diagnostic and prognostic biomarkers in STEMI.

Automated summary

Despite advancements in diagnosis and treatment, coronary artery disease (CAD) and especially ST-elevation myocardial infarction (STEMI) remain major causes of morbidity and mortality worldwide. Early and accurate diagnosis of cardiac dysfunction is crucial for improving prognosis and outcomes in STEMI patients. Recently, microRNAs (miRNAs) have gained attention as potential biomarkers for myocardial infarction (MI) and acute coronary syndromes (ACS), due to their involvement in heart development, various cardiac processes, and as indicators of cardiac damage. This review discusses the current knowledge on cardiac miRNAs and their functions, with a focus on their potential use as novel circulating diagnostic and prognostic biomarkers in STEMI.